Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

S&P Dow Jones Indices said that Guidewire Software Inc. (GWRE) will replace Arrowhead Pharmaceuticals Inc. (ARWR) in the S&P MidCap ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...

Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by ...

PASADENA, Calif.—Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biotechnology company currently valued at $2.45 billion, sold a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), which has seen its stock decline over 50% in the past year according to InvestingPro data, recently reported that Patrick O'Brien, the company's ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence ...